be_ixf;ym_202002 d_25; ct_50

Select Page

Nick Tate

Nick TateNick Tate Senior Editorial Manager for Bold Profits Daily, Profits Unlimited and Paul Mampilly’s other premium trading publications.

Nick Tate is the senior editorial manager for Bold Profits Daily, Profits Unlimited and Paul Mampilly’s other premium trading publications.

As a best-selling author, seasoned journalist and TV commentator specializing in health care, finance and biotech, Nick is all about big ideas and innovations — always keeping his followers informed on the next big thing.

His work has appeared in The Miami Herald, The Atlanta Journal-Constitution, South Florida Business Journal, Newsmax Magazine, South Florida Sun Sentinel, Boston Herald, and on Newsmax TV and the Al Jazeera network.

His top-selling book, the ObamaCare Survival Guide, was on the Publishers Weekly and The New York Times best-sellers lists for 22 weeks — reaching No. 1 on The Times list for paperback advice books.

Tate also co-authored DaVinci’s Baby Boomer Survival Guide: Live, Prosper, and Thrive in Your Retirement. And he published two other books — the Encyclopedia of Natural Healing and The Sick Building Syndrome — following a year-long journalism fellowship at the Harvard School of Public Health.

Tate’s three-decades-long commitment to keeping the public well-informed is why Banyan Hill Publishing recruited him in 2018 to join Paul Mampilly’s team. You can now read Nick’s weekly analysis in Bold Profits Daily as he guides over 130,000 readers on the best ways to grow their wealth.

Nick Tate's Articles

Biotech is Leading the $8 Billion IPO Surge - Last year was a high-water mark for biotech companies going public — with 60. But the Class of 2019 is on track to beat that record, with 38 biotech IPOs since January 1. Here’s how to capitalize on the red-hot biotech IPO market.
Artificially intelligent robots and other “thinking” machines are entering the workforce in health care, banking and retail. They can not only help you with your health, finances and store purchases, but offer a great investment opportunity too. Meet Pepper: The New Face of AI Robotics - Artificially intelligent robots and other “thinking” machines are entering the workforce in health care, banking and retail. They can not only help you with your health, finances and store purchases, but offer a great investment opportunity too.
271% Gain in 2 Weeks From Biotech Rebound - See how you could gain 271% in two weeks using Paul’s Wall Street insider strategy, designed to beat market manipulators at their own game.
This one trick that market manipulators use to drive stock prices down can help you spot stocks as they're about to rebound. Buy Into Stocks That Are Rebounding for Rocket Returns - “Buy low, sell high.” It’s investors’ mantra. But this one trick that market manipulators use to drive stock prices down can help you spot the right ones at the right time — just as they’re about to skyrocket.
Beyond Meat’s stock skyrocketed 163% when it went public earlier this month. It’s proof the global market for meatless burgers is booming. Meatless Burger IPO Nets Investor-Advocate 1,570% Gains - Beyond Meat’s stock skyrocketed 163% when it went public earlier this month. It’s proof the global market for meatless foods is booming and that IPOs are a great way to invest in companies and causes you believe in — and pocket big profits at the same time.
The global organ-transplantation market is projected to hit $51 billion in just six years. Here’s how to double your money and cash in with an ETF, and double your money in a year. TransMedics’ $105 Million IPO Spotlights Organ Transplant Opportunity - The global organ-transplantation market is projected to hit $51 billion in just six years. Here’s how to double your money and cash in with an ETF, and double your money in a year.
Beyond Meat could be valued at $1.2 billion when it goes public. It’s proof the global market for meatless foods is booming. Beyond Meat IPO – A Stock Play for the Meatless Burger Boom - Beyond Meat could be valued at $1.2 billion when it goes public. It’s proof the global market for meatless foods is booming. With 40 million Americans going vegan or vegetarian, now’s the time to buy into the mega meatless trend.
We are at the forefront of a massive biotech opportunity. Two big diabetes advances are going to make needles obsolete, and investors wealthy. 4,500% Biotech Opportunity: Needle-Free Diabetes Devices - We are at the forefront of a massive biotech opportunity. Two big diabetes advances are going to make needles obsolete, and investors wealthy.
Telemedicine is reviving the idea of a house call, letting teledocs “meet” with patients via video. With telehealth set to become a $130 billion industry by 2025, now’s a great time to capitalize on the investment and health care opportunity it presents. 2 Telehealth Stocks to Capitalize on Sector Growth - Telemedicine is reviving the idea of a house call, letting teledocs “meet” with patients via video. With telehealth set to become a $130 billion industry by 2025, now’s a great time to capitalize on the investment and health care opportunity it presents.
Artificially intelligent robots and other “thinking” machines are entering the new high-tech health care workforce. Here’s two ways to profit. SoftBank Robotics is Changing the Face of Health Care - Artificially intelligent robots and other “thinking” machines are entering the new high-tech health care workforce. They will not only help you be healthier, but investing in the new tech could make you wealthier as well. Here’s two ways to do it.

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

I am up $20,070 in closed positions from Feb. 18 through March 7.

- Bob Rowe

I started your system in December … I am ahead $29,000 … I put total faith in you and your system and it has worked for me very nicely. Thanks again I sure like your humble approach about this whole thing

- Dale Leiffer

I have made a little over $4,000 while being cautious.

- Chuck Goss